Bacterial Toxin Shows Promise in Slowing Colorectal Cancer Growth

A bacterial toxin, produced by the cholera bacterium Vibrio cholerae, is showing promise as a potential new weapon against colorectal cancer. Researchers at Umeå University in Sweden have discovered that this toxin, known as MakA, can selectively slow the growth of colorectal tumors without causing detectable harm to healthy tissue.

The groundbreaking study, initially December 1, 2025, reveals that the toxin exploits a specific vulnerability within colorectal tumors, targeting cancer cells and hindering their proliferation while sparing normal intestinal cells. Further research published on January 14, 2026, details these findings.

The toxin appears to work by disrupting the overactive DNA repair processes within colorectal cancer cells, selectively inducing cell death. Tumors treated with MakA demonstrated a significant reduction in growth rate, and no measurable toxicity was observed in surrounding healthy tissues. This discovery could inspire precision medicine approaches, potentially reducing the common side effects associated with chemotherapy, a major challenge in oncology.

“The substance not only kills cancer cells directly. It reshapes the tumour environment and helps the immune system to work against the tumour without damaging healthy tissue,” explains Sun Nyunt Wai, professor at Umeå University and one of the lead authors of the study.

How MakA Targets Cancer Cells

A key aspect of the research lies in the toxin’s ability to accumulate specifically within tumor tissue, increasing the rate of cancer cell death and reducing their ability to multiply. Simultaneously, MakA alters the cellular environment within the tumors, increasing the number of innate immune cells, particularly macrophages and neutrophils, which further contributes to inhibiting tumor growth.

Macrophages and neutrophils are types of white blood cells that play a crucial role in the body’s immune response. By increasing their presence within the tumor microenvironment, MakA essentially enlists the body’s own defenses to fight the cancer.

A Two-Pronged Attack

The mechanism of action appears to be a “double-barreled” attack. MakA doesn’t simply kill cancer cells; it fundamentally changes the tumor’s surroundings, making it more susceptible to immune attack. This dual approach – direct cancer cell killing combined with immune system enhancement – represents a significant advancement over treatments that rely on a single mechanism.

Minimal Side Effects in Preclinical Studies

Importantly, the researchers observed no harmful inflammation in mice treated with MakA. Unlike chemotherapy, this approach appears to spare the body from becoming a “war zone,” as described in recent reporting. There were no adverse effects on body weight, organ function, or systemic inflammation, even after repeated dosing in preclinical models.

Colorectal Cancer: A Global Health Challenge

Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths globally, accounting for approximately 10% of all cancer diagnoses. Current treatments – surgery, radiation, and chemotherapy – are often effective but can also have significant side effects. The increasing incidence of colorectal cancer worldwide underscores the need for alternative treatment strategies.

Looking Ahead: From Lab to Clinic

While the results are promising, it’s crucial to emphasize that human trials have not yet been conducted. Researchers stress the need for further investigation to validate MakA’s anti-cancer potential in other models and to assess its suitability for future clinical use. The study was funded by the Swedish Research Council, the Swedish Cancer Society, and the Kempe Foundation.

The research team is now focused on understanding the long-term effects of MakA treatment and identifying potential biomarkers that could predict which patients are most likely to benefit from this approach. Further studies will also explore the possibility of combining MakA with existing cancer therapies to enhance their effectiveness.

This research offers a glimmer of hope in the ongoing fight against colorectal cancer, suggesting that harnessing the power of bacterial toxins could lead to a new generation of targeted cancer treatments with fewer side effects.